After observing deep, MRD-negative responses at their starting dose, Colonia Therapeutics unconventionally tested a lower dose level. This counter-intuitive strategy aims to identify the minimum effective dose, which is crucial for maximizing the safety profile (the therapeutic window) and improving commercial viability through lower manufacturing costs.

The failure of an adjuvant trial for the TKI pazopanib was likely caused by a protocol change that reduced the dose to manage transaminitis. While well-intentioned to improve tolerability and adherence, the lower dose was sub-therapeutic. This serves as a critical lesson that managing side effects by compromising dose can nullify a drug's potential efficacy.

For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.

Data on Enfortumab Vedotin suggests that for modern therapies, maintaining patients on treatment longer via a lower, more tolerable starting dose is more important than administering the maximum labeled dose upfront, a concept inherited from the cytotoxic chemotherapy era.

A key nuance in managing ponatinib for Ph+ ALL is a response-adapted dosing strategy. Patients are typically started at a 30mg dose, which is then reduced to 15mg once a good minimal residual disease (MRD) response is achieved. This approach aims to maintain efficacy while mitigating long-term toxicity.

Concerns over arterial events caused physicians to start CML patients on lower, less effective doses of ponatinib. Data shows a start-high (45mg) then reduce strategy is more effective for disease control and safely mitigates side effect risks, contrary to clinical practice.

A majority of patients on the lenvatinib/pembrolizumab regimen require dose reductions due to toxicity. Crucially, clinical trial data shows no significant change in progression-free survival for patients on lower doses, an important point for patient reassurance.

Clinicians recommend starting abemaciclib at 100mg BID, rather than the standard 150mg, to mitigate initial GI toxicity. This dose-escalation approach, supported by the TRADE study, improves long-term adherence and allows more patients to reach the target dose without discontinuing.

Although 60% of patients required a dose reduction for talazoparib, the expert argues for the higher starting dose. He believes it secures a more durable and long-lasting response, which is crucial, even if it necessitates later dose adjustments due to toxicity like anemia.